Company: IMCR
Filing Date: 2025-08-07
Form Type: 10-Q
Source: 0001671927-25-000014
Chunk: 15

Company: Immunocore Holdings plc
Filing Date: 2025-08-07
Form: 10-Q
Item: Part I, Item 1
Chunk 15
---
Item 1.    Financial Statements

Immunocore Holdings plc

Condensed Consolidated Balance Sheets

(Unaudited) (In thousands, except share and per share data)

June 30,2025December 31,2024AssetsCurrent assetsCash and cash equivalents$487,933 $455,731 Marketable securities394,878 364,645 Accounts receivable, net69,761 63,009 Prepaid expenses and other current assets44,270 41,033 Inventory, net5,456 5,446 Total current assets1,002,298 929,864 Property and equipment, net9,548 10,092 Operating lease right of use assets, net39,428 37,643 Deferred tax assets, net14,077 14,790 Other non-current assets17,036 17,117 Total assets$1,082,387 $1,009,506 Liabilities and shareholders’ equityCurrent liabilitiesAccounts payable$23,856 $25,100 Accrued expenses and other current liabilities143,785 185,534 Deferred revenue, current594 — Operating lease liabilities, current1,843 1,547 Total current liabilities170,078 212,181 Accrued expenses, non-current83,960 — Deferred revenue, non-current 5,247 5,434 Operating lease liabilities, non-current42,561 40,162 Interest-bearing loans and borrowings392,060 391,013 Total liabilities693,906 648,790 Commitments and contingencies (Note 10)Shareholders’ equityOrdinary shares (voting and non-voting), £0.002 par value, most recent authority to allot up to a maximum nominal value of £149,633 and £97,454 shares as of June 30, 2025 and December 31, 2024, respectively, and 50,372,068 and 50,064,860 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively. 135 135 Deferred shares, £0.0001 par value, 5,793,501 shares authorized, issued and outstanding as of June 30, 2025 and December 31, 2024.1 1 Additional paid-in capital1,215,997 1,190,104 Acc